121-Unlock Immunotherapy Resistance by CXCR4 partial agonist

This article reports on a novel immunotherapy strategy for gastric and other gastrointestinal cancers using TFF2-MSA, a CXCR4 partial agonist peptide, in combination with anti-PD-1 treatment. Researchers demonstrate that TFF2-MSA synergistically enhances anti-PD-1 efficacy by selectively reducing immunosuppressive neutrophils (PMN-MDSCs), particularly the CXCR4-highly-expressing Hdc-GFP+ subset, i...去小宇宙查看完整单集简介
前往小宇宙评论区与主播互动